ARTICLE | Company News
Hebrew University of Jerusalem, BioTheryX deal
May 16, 2016 7:00 AM UTC
The university’s Yissum Research Development Co. and BioTheryX partnered to develop and commercialize casein kinase 1 alpha ( CSNK1A; CKI-alpha) inhibitors to treat hematologic and solid malignancie...